Plain-English translation of NCT05933174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether giving patients a simple question sheet helps them have better conversations with their doctors about their diabetes medications. Researchers want to help people taking sulfonylureas—an older class of diabetes drugs—explore newer, safer alternatives that may work better for them.
Sulfonylureas are an older diabetes medication that can sometimes cause low blood sugar and other side effects. Newer medications are now available that are safer and more effective, but many patients and doctors aren't aware of these alternatives or haven't discussed switching.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll either receive a question sheet to help guide a conversation with your doctor, or an informational brochure about diabetes medications (depending on which group you're assigned to). You'll then answer short surveys every 3 months for your first year to let researchers know whether you discussed medication alternatives with your doctor and how you're feeling on your current treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Ian J. Neeland, MD
Collaborators
American Heart Association
Enrollment target
~220 participants
Started
October 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
45 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ian Neeland, MD
University Hospital Cleveland Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.